According to filings with the U.S. Securities and Exchange Commission, Voyager Therapeutics is raising $39,032,821.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Al Sandrock played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Voyager Therapeutics
Voyager Therapeutics (Nasdaq: VYGR) is a biotechnology company dedicated to breaking through barriers in gene therapy and neurology. The potential of both disciplines has been constrained by delivery challenges; Voyager is leveraging cutting-edge expertise in capsid discovery and deep neuropharmacology capabilities to address these constraints. Voyagers TRACER AAV capsid discovery platform has generated novel capsids with high target delivery and blood-brain barrier penetration at low doses, potentially addressing the narrow therapeutic window associated with conventional gene therapy delivery vectors. This platform is fueling alliances with Pfizer Inc., Novartis and Neurocrine Biosciences as well as multiple programs in Voyagers own pipeline. Voyagers pipeline includes preclinical programs in Parkinsons disease, Alzheimers disease, and amyotrophic lateral sclerosis (ALS), each with validated targets and biomarkers to enable a path to rapid potential proof-of-biology.

To learn more about Voyager Therapeutics, visit http://www.voyagertherapeutics.com/

Contact:
Al Sandrock, Chief Executive Officer
857-259-5340
https://www.linkedin.com/in/al-sandrock-2706077/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.